

Dose-Dependent Inhibitory Effect of Nitric Oxide on Embryo Development

Sea-Hee Park, Bo-Sun Joo*, Hwa-Sook Moon*, Yoon-Yeon Kim**,
Jae-Dong Cho**, Ho-Sung Kang, and Han-Do Kim

Department of Molecular Biology, College of Natural Science,
Pusan National University, Pusan 609-735,

*Infertility Clinic, Moon Hwa Hospital, Pusan 601-062,

**Cho Jae Dong OB/GY, Chang-Won 641-530, Korea

Nitric Oxide

, * , * , ** , ** , ,
 , * , **

: 233-7

Tel : 0551-253-2111

Fax : 0551-253-2114

INTRODUCTION

Approximately 14-40% of infertile couples have infertility caused by immunologic disorders which result from the production of antisperm antibody in humoral immune response¹ and the soluble products of activated lymphocytes and macrophages in cellular immune response^{2,3}.

Especially, endometriosis which is inflammatory state characterized by the presence and growth of ectopic endometrial tissue outside the uterine cavity, occurs at 20-40% of high incidence in infertile women⁴. As peritoneal fluid is able to go into the oviductal cavity, changes of cellular and hormonal components within peritoneal fluid may influence the early reproductive processes such as fertilization and early embryo development by modulating the microenvironment that surrounds the embryo⁵. Peritoneal fluid in women with endometriosis has been reported to increase the number of activated macrophages⁴ and the production of cytokines such as interleukin-1 (IL-1)⁶, interleukin-6 (IL-6)⁷ and tumor necrosis factor- α (TNF- α)^{8,9}. These cytokines are known to have adverse effects on sperm cell function, fertilization and embryo development¹⁰. However, the correct mechanism for this inhibition is unclear.

It is an established fact that these cytokines stimulate macrophages to produce nitric oxide (NO) during conversion of L-arginine to L-citrulline by NO synthase¹¹. It has been reported that NO plays important roles in various physiological systems. The physiologic actions of NO are regulating smooth muscle relaxation, platelet aggregation and adhesion, cell growth, neurotransmission, apoptosis and immune response¹². Since the cells of these systems are integral parts of the reproductive organs, NO is thought to play an important role in reproduction. Indeed, many studies have demonstrated that NO regulates pulsatile hypothalamic GnRH secretion¹³, human granulosa-luteal cell steroidogenesis¹⁴, ovulation¹⁵ and penile erection¹⁶. Therefore, it is suggested that the increased production of NO from the activated macrophage by endometriosis or certain other causes may affect directly or indirectly fertilization and embryo development causing infertility.

NO induces cell death via apoptosis or necrosis. This effects of NO were thought to be solely mediated via activation of 3',5'-cyclic guanosine monophosphate

(c-GMP)¹⁷. However, recent studies have demonstrated that NO can also induce biological effects via non-cGMP dependent pathways^{18,19}.

Therefore, this study was performed to understand the effect of NO on embryo development using sodium nitroprusside (SNP), stable NO donor and peritoneal fluids collected from women undergoing laparoscopic operation. NO concentration in PF was measured to determine whether NO level within PF correlates with the embryo development. We also investigated the occurrence of apoptosis following by treatment of SNP and the effect of cGMP analogue on embryo development to understand the mechanism and the pathway for the action of NO.

MATERIALS AND METHODS

1. Materials

The original stock of C57BL/6 × CBA/Ca hybrid F1 female mice was purchased from Korean Laboratory Animal Center (Korea). PMSG (pregnant mare's serum gonadotropin), hCG (human chorionic gonadotropin), hyaluronidase, mineral oil, sodium nitroprusside, *N*-(1-naphthyl)-ethylenediamine (NED), sulphanilamide, H₃PO₄, NaNO₂, 8-bromo-cGMP, trypan blue, Hoechst 33342 and sodium citrate were purchased from Sigma Chemical Company (St. Louis, MO). Synthetic serum substitute (SSS) was purchased from Irvine Scientific (Santa Ana, CA). Culture dish (60mm) was purchased from Falcon Inc. (Becton Dickinson, USA). SNP and 8-bromo-cGMP was prepared as a concentrated stock in serum free modified human tubal fluid (m-HTF) and stored at -20 until use.

2. Zygote embryo collection and culture

Zygote embryos were obtained from superovulated hybrid F1 female mice (4-6 weeks old). Superovulation was induced by intraperitoneal injections of 5 IU of PMSG followed by 5 IU of hCG after 48 hours. Mating was confirmed by the appearance of a vaginal plug in the next morning. Zygotes were collected from excised oviducts 18 to 20 hours after hCG injection and cultured in m-HTF medium supplemented with 10% SSS at a 37 incubator in 5% CO₂ for 4 days. Adherent

cumulus cells were removed by micropipetting in serum free modified human tubal medium (m-HTF) containing 0.1% hyaluronidase.

3. Treatment of SNP and cGMP-analogue

Zygotes were treated with the various concentration of SNP (0, 100 nM, 10 μ M, 50 μ M, 100 μ M, 200 μ M, 1mM) or 8-bromo-cGMP, an analogue of cGMP (0, 50 μ M, 100 μ M, 500 μ M, 1mM). And 200 μ M SNP was treated at 2-cell, 4-cell and 8-cell embryonic stage to examine the effect of SNP is dependent on SNP treatment stages. Experiments were repeated three or more times and 10-20 embryos were usually used in each experiment.

4. Peritoneal fluid processing

Peritoneal fluid (PF) was obtained from 42 women undergoing laparoscopy for various causes (e.g. endometriosis, myoma) and was centrifuged at 800g for 10 minutes within 30 minutes after collection. The supernatant was divided into two parts. One part was inactivated complement proteins in a water bath at 56 for 30 minutes and stored at -20 to use for embryo culture. The other was immediately stored to assay NO concentration. Before use in culture, an aliquot of PF was filtered (0.22 μ m filter, Millex GS, Millipore Corporation, Bedford, MA) and 1ml of 10% PF in m-HTF medium was provided for *in vitro* zygote embryo culture. The groups of control were cultured in m-HTF medium containing 10% SSS. Experiments was repeated three times for each PF sample and 10-20 zygote embryos were used in each experiment.

5. Measurement of NO

NO concentration in PF was measured using Griess method²⁰. Griess assay reagents [Nitroprusside 0.2% *N*-(1-naphthyl)-ethylendiamine (NED) and 2% sulphanilamide in 5% concentrated H₃PO₄] were premixed and then incubated with a peritoneal fluid sample (ratio 1:1) to form a purple azo dye, and absorption was determined at a wavelength of 540 nm by ELISA Reader. NaNO₂ was used to generate standard curve, and NO concentration was calculated from standard curve.

6. Detection of Apoptosis in embryos

To observe the occurrence of apoptosis, normal developing 2-cell embryos, which was not treated with SNP, and 2-cell embryos arrested by treatment of 200 μ M SNP were stained with trypan blue and incubated with Hoechst 33342 working solution for 3 min. Hoechst 33342 (Sigma) dye was prepared as stock solution (1mg/ml) and added to 2.3% sodium citrate in ethanol (10 μ l/ml) for working solution. The stained samples were mounted and apoptosis was examined under a fluorescence microscope.

7. Statistical analysis

Statistical analysis was performed by the Student's *t*-test and a *p* value of <0.05 was considered significant.

RESULTS

1. Inhibition of mouse embryo development by SNP treatment

To investigate the effect of nitric oxide on mouse embryo development, SNP was treated to mouse zygote culture media with various concentration (0 to 1mM). The rate of embryo development to blastocyst in the different concentration of SNP is shown in Fig. 1. The addition of SNP inhibited mouse embryo development in a dose-dependent manner. The rates of embryo development were 71% in control, 53% in 0.1 μ M, 48% in 10 μ M, 27% in 50 μ M, 8% in 100 μ M, 0% in 200 μ M and 1mM. Especially above 200 μ M of SNP mouse embryo development was completely arrested and degenerated since 2-cell embryonic stage. To determine whether this effect of SNP was treatment stage-specific, 200 μ M SNP was treated at 2-cell, 4-cell and 8-cell embryonic stage. As showed in Table 1, mouse embryo did not develop to blastocyst whenever SNP was treated.

2. The relationships between the level of NO in PF and embryo development

The addition of PF in mouse embryo culture media resulted in the different development rate. We measured the concentration of NO in PF to determine whether

this different rate was caused by changes of cellular component within PF. NO concentration was different from each PF sample ranged from 0.79 μ M to 4.4 μ M. PF was divided into 6 groups according to its NO level and the rates of embryo development were represented in Table 2. The rate of embryo development was significantly lower in group V (26.5 \pm 16.6%) and group VI (29.2 \pm 11.0%) compared with control (62.8 \pm 6.1%), which was cultured in medium with 10% SSS (p<0.05). However, the rate of embryo development in 2.5 μ M or less (group I to IV) was similar compared with that of control.

3. Inhibitory effect of NO on the mouse embryo development via cGMP-dependent or independent pathway

To determine whether this effect of NO on mouse embryo development was mediated by the elevating level of cGMP, 8-bromo-cGMP was added to embryo culture media. As noted in Fig.2, embryo development was not influenced by 8-bromo-cGMP regardless of the treated concentrations (50 μ M to 1mM). This result suggests that NO may inhibit mouse embryo development through cGMP-independent pathway.

4. Detection of apoptosis in embryo arrested by SNP treatment

To investigate whether the arrest of embryo development following SNP treatment resulted from cell death via NO-mediated apoptosis, we examined the nucleus fragmentation in 200 μ M SNP treated 2-cell embryos. Compared with normal developing embryos, the morphological changes of nucleus were not detected in embryos treated with SNP and the size of nucleus is equal to that of control (Fig. 3).

DISCUSSION

NO can pass easily into the intracellular area and have many different effects on cell metabolism in the biology, physiology, and pathophysiology of reproduction¹². Because NO is a free radical, it is degraded easily and has very short life span. Thus

most studies used a more stable nitric oxide donor to elucidate the role of NO *in vitro*. SIN-1, sodium nitroprusside (SNP), SNAP are representative nitric oxide donor. Among them, SNP released only NO *in vitro* cell culture system, while other two donors released superoxide anion or/and hydrogen peroxide as well as NO²¹, and SNP concentration in cell is known to be in proportion to production of NO²². Weinberg *et al.*²³ reported that SNP reduced sperm motility and this inhibition was blocked by the NO quencher hemoglobin. This suggests that SNP is more suitable to study the effect of only NO compared with other NO donors.

Our present study showed that mouse embryo development to blastocyst was inhibited dose-dependently by SNP, especially reduced at high concentration of 100 μM or more. However, this SNP-induced inhibitory effect on embryo development was not stage-specific because embryo development was inhibited regardless of SNP treatment stages. We also found that embryo development was severely arrested in media containing PF with the higher concentration of NO than in media containing qualified controlled serum. It has been recognized that PF is able to go into the oviductal cavity and may influence the early reproductive processes by modulating the microenvironment that fertilization and early embryo development occur. These results imply that high concentration of NO may adversely affect embryo development, and that changes of component within PF especially such as increased concentration of NO can be closely associated with embryo development.

Previously, many studies have observed that the level of macrophage, cytokines and other cellular components were increased and activated with the extent of pelvic disease and inflammation^{5,8,9}. PF in women with endometriosis adversely affected the cleavage of mouse two-cell embryos²⁴ and contained high concentration of cytokines such as TNF- and IL-1¹⁰. However, the correct mechanism for interaction between these cytokines in PF and embryo toxicity has not been elucidated yet. A common pathway of the action of TNF- on various cell systems is the induction of an inducible nitric oxide synthase (iNOS), which results in the generation of NO. Thus it is possible that a certain disease such as endometriosis or other factors stimulate the production of cytokines, which subsequently induce the production of NO thereby directly affecting embryo development.

Generally the effects of NO were known to be mediated via activation of soluble

guanylate cyclase and guanosine 3',5'-cGMP, which inhibits Ca^{2+} influx and activates its efflux, resulting in a lower intracellular $[\text{Ca}^{2+}]$. Decreased intracellular $[\text{Ca}^{2+}]$ can inactivate PKC, and thus inhibit PKC-dependent cell proliferation²⁵. But, the inhibitory effect of NO on mouse embryo development may be not mediated by a cGMP-dependent pathway, since the addition of 8-bromo-cGMP, agent which raises cellular cGMP, did not affect embryo development regardless of treated concentration. This result is supported by recent studies, which suggest that NO can induce its biological effects via non-cGMP-dependent pathways by forming high-affinity-nitroso complexes with a variety of metal compound or binding the heme-containing proteins and iron-sulphur-containing proteins^{14,18,19}.

The effects of NO via these pathway may be dependent on dose and the cell type. One hundred micromole of SNP was shown to inhibit sperm motility²⁶, while lower concentration of SNP (100nM or less) was beneficial to the maintenance of post-thaw sperm motion, viability and motility²⁷. And NO has the double-edged role in inducing apoptosis. High level of NO induced by pathophysiological conditions stimulates apoptosis while the continuous release of endothelial NO inhibits apoptosis²⁸. We investigated whether the inhibition of embryo development by higher concentration of SNP caused by inducing apoptosis of embryo, but apoptotic characteristics did not found in embryos arrested by treatment of SNP.

Another possibility we can consider for this inhibitory effect is the inhibition of embryonic-stage specific protein synthesis by SNP. A lot of stage-specific proteins are necessary for normal embryo development. NO is capable to posttranslationally interfere with heme proteins and enzymes containing iron-sulfur cluster or to modulate enzyme activity by S-nitrosylation²⁹. Thus, the further study is needed to prove the correct mechanism for the inhibition of embryo development.

In conclusion, high concentration of SNP and PF containing high amounts of NO inhibited early embryo development. This result suggests that *in vivo*, if there is increase of NO level in reproductive systems such as peritoneum and tubal fluid by certain causes, this may correlate with infertility by causing damage to embryo.

REFERENCES

1. Naz RK, Menge AC: Antisperm antibodies. Origin, regulation, and sperm reactivity in human infertility. *Fertil Steril* 1994; 61: 1001-13.
2. Hill JA, Cohen J, Anderson DJ. The effects of lymphokines and monocytes on human sperm fertilizing ability in the zona-free hamster egg penetration test. *Am J Obstet Gynecol* 1989; 160: 1154-59.
3. Jung BJ, Lee SH, Hur M. The efficacy on the immunotherapy with paternal lymphocytes in unexplained infertility. *Korean J Fertil Steril* 1997; 24: 293-300.
4. Ramey JW, Archer DF. Peritoneal fluid: its relevance to the development of endometriosis. *Fertil Steril* 1993; 60: 1-14.
5. Badawy SZA, Cuenca V, Marshall L, Munchback R, Rinas AC, Coble DA. Cellular components in peritoneal fluid in infertile patients with and without endometriosis. *Fertil Steril* 1984; 42: 704-8.
6. Fakih H, Baggett B, Holtz G, Tsanh KY, Lee JC, Williamson HO. Interleukin-1: a possible role in the infertility associated with endometriosis. *Fertil Steril* 1987; 47: 213-7.
7. Harada T, Yoshioka H, Yoshida S, Iwabe T, Onohara Y, Tanikawa M, Terakawa N. Increased interleukine-6 levels in peritoneal fluid of infertile patients with active endometriosis. *Am J Obstet Gynecol* 1997; 176: 593-7.
8. Halme J, Hammond MG, Hulka JK. Retrograde menstruation in healthy women and in patients with endometriosis. *Obstet Gynecol* 1984; 64: 151-4.
9. Eisermann J, Michael JG, Jorge P, Odem RR, Collins JL. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. *Fertil Steril* 1988; 50: 573-9.
10. Taketani Y, Kuo TM, Mizuno M. Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. *Am J Obstet Gynecol* 1992; 167: 265-70.
11. Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. *Annu*

- Rev Biochem 1994; 63: 175-95.
12. Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. *Human Reprod* 1998; 4: 3-24.
 13. Moretto M, Lopez FJ, Negro-Vilar A. Nitric oxide regulates luteinizing hormone-releasing hormone secretion. *Endocrinology* 1993; 133: 2399-2402.
 14. Van Voorhis BJ, Dunn MS, Snyder GD, Weiner CP. Nitric oxide: An autocrine regulator of human granulosa-luteal cell steroidogenesis. *Endocrinology* 1994; 135: 1799-1806.
 15. Hwsia JS, Preutthipan S, Maguire MP, Chang TS, Wallach EE, Dharmarajan AM. Nitric oxide modulates human chorionic gonadotropin-induced ovulation in the rabbit. *Fertil Steril* 1997; 67: 548-52.
 16. Holmquist F, Stief CG, Jones U. Effect of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. *Acta Physiol Scand* 1991; 143: 299-304.
 17. Murad F. Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. *Adv Phamacol* 1994; 26: 19-33.
 18. Brunswig-Spickenheier B, Mukhopadhyay AK. Stimulation of nitric oxide-cyclic guanosine monophosphate pathway in bovine ovarian theca cells by tumor necrosis factor- α (TNF- α). Is this pathway implicated in the TNF- α -induced inhibition of uterine hormone-stimulated prorenin production. *Biol Reprod* 1997; 57: 700-6.
 19. Kroncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection ; How, Why, When, and Where? *NITRIC OXIDE: Biol Chem* 1997; 1: 107-20.
 20. Marzinzig M, Nussler AK, Stadler J, Marzinzig E, Barthlen W. Improved methods to measure end products of nitric oxide in biological fluids: Nitrite, Nitrate, and S-Nitrosothiols. *NITRIC OXIDE: Biol Chem* 1997; 1: 177-89.
 21. Ioannidis I, Groot H. Cytotoxicity of nitric oxide in Fu 5 rat hepatoma cells; evidence for co-operative action with hydrogen peroxide. *Biochem J* 1993; 296:

341-5.

22. Kowulak EA, Seth P, Fung HL. Metabolic activation of sodium nitroprusside in vascular smooth muscle. *J Pharmacol Exp Ther* 1992; 262: 916-22.
23. Weinberg JB, Doty E, Bonaventura J, Haney AF. Nitric oxide inhibition of human sperm motility. *fertil steril* 1995; 64: 408-13.
24. Morcus RN, Gibbons WE, Findley WE. Effects of peritoneal fluid on in vitro cleavage of 2-cell mouse embryos: possible role in infertility associated with endometriosis. *Fertil Steril* 1985; 44: 678-83.
25. Khatib AM, Siegfried G, Quintero M, Mitrovic DR. The mechanism of inhibition of DNA synthesis in articular chondrocytes from young and old rates by nitric oxide. *NITRIC OXIDE: Biol Chem* 1997; 1: 218-25.
26. Rosselli M, Dubey RK, Imthurn B. Effect of nitric oxide on human spermatozoa: evidence that nitric oxide decreases sperm motility and induces sperm toxicity. *Human Reprod* 1995; 10: 1786-90.
27. Hellstrom WJG, Bell M, Wang R. Effect of sodium nitroprusside on sperm motility, viability, and lipid peroxidation. *fertil steril* 1994; 61: 1123-8.
28. Dimmeler S, Zeiher AM. Nitric oxide and apoptosis: Another paradigm for the double-edged role of nitric oxide. *NITRIC OXIDE: Biol Chem* 1997; 1: 275-81.
29. Stamler JS, Jaraki O, Osborne J. Nitric oxide circulates in mammalian plasma primarily as a S-nitroso adduct of serum albumin. *Proc Natl Acad Sci* 1992; 89: 7674-6.

Figure Legends

Figure 1. Effect of SNP on mouse embryo development.

SNP was treated with various concentrations (control, 100 nM, 10 μ M, 50 μ M, 100 μ M, 200 μ M, 1 mM) to embryo culture medium. Embryos were cultured from zygote to blastocyst and embryonic development was examined. Development rate was expressed with % of developing to blastocysts from zygotes. Data was mean of three experiments. Values in vertical bar are the number of embryos reached to blastocyst/the total number of embryos provided for experiment. * $p < 0.05$

Figure 2. Effect of cGMP-analogue (8-bromo-cGMP) on mouse embryo development. 8-bromo-cGMP was treated with concentrations of 0 to 1 mM to embryo culture medium. Embryos were cultured from zygote to blastocyst and embryonic development was examined and development rate was expressed with % of developing to blastocysts from zygotes. Data was mean of three experiments. Values in vertical bar are the number of embryos reached to blastocyst/the total number of embryos provided for experiment. * $p > 0.05$

Figure 3. Fluorescence micrographs of 2-cell embryos stained with Hoechst 33342 for detection of apoptotic bodies. Zygote embryos were culture in m-HTF medium without (Fig.3a) or with (Fig.3b) 200 μ M SNP. After 24 hours, 2-cell embryos were stained with Hoechst 33342 and observed at $\times 400$ by fluorescence microscope.

Table 1. Effect of SNP on mouse embryo development depending on the SNP treatment stages.

SNP* treatment stage	No. of developed embryos to				
	zygote	2-cell	4-cell	morula	blastocyst
control	60	51	51	48	48
zygote	60	48	0	0	0
2-cell	-	60	30	16	0
4-cell	-	-	54	27	0
8-cell	-	-	54	30	0

* 200 μ M SNP treated to 2-cell, 4-cell and 8-cell embryonic stage during zygote embryos were cultured to blastocyst stage.

Table 2. Effect of peritoneal fluid on mouse embryo development according to the level of NO in peritoneal fluid

Group (n [*])	NO level (μM) (Mean ± SEM)		No. of embryos	% of developed embryos [†] to			
				2-cell	4-cell	Morula	Blastocyst
	control		120	87.4 ± 2.9	85.2 ± 3.3	76.9 ± 4.5	62.8 ± 6.1
I (9)	1.0 (0.84 ± 0.05)		90	96.6 ± 2.1	92.7 ± 3.0	84.9 ± 2.9	68.3 ± 8.6
II (7)	1.0	1.5 (1.20 ± 0.07)	70	100 ± 0.0	98.2 ± 1.7	91.9 ± 4.0	70.0 ± 8.0
III (5)	1.5	2.0 (1.81 ± 0.07)	50	95.5 ± 4.4	95.8 ± 4.1	93.0 ± 4.1	91.9 ± 5.2 ^a
IV (8)	2.0	2.5 (2.15 ± 0.03)	80	90.2 ± 3.6	89.9 ± 4.6	82.7 ± 4.9	71.2 ± 5.2
V (5)	2.5	3.0 (2.68 ± 0.04)	50	85.5 ± 11.9	70.5 ± 23.6	40.3 ± 24.9 ^a	26.5 ± 16.6^a
VI (8)	< 3.0	(4.36 ± 0.05)	80	89.0 ± 3.3	69.8 ± 12.3	42.8 ± 23.6 ^a	29.2 ± 11.0^a

Note : Peritoneal fluid was obtained from 42 women with endometriosis of other causes by laparoscopy

* ; n = number of peritoneal fluid sample

[†] ; Mean ± SEM

^a ; p<0.05 (versus control)

= =

: (nitric oxide; NO)

,

NO 가

.

: 1 (C57BL × CBA/Ca) 1

10% synthetic serum substitute가 가 modified human tubal fluid 4
(). sodium

nitroprusside (SNP) 0 1mM 가 , 200 μM

SNP 2-, 4-, 8-

가 ,

42

SSS

NO Griess

apoptotic body H33342 3

mean ± SEM

: SNP

, 100μM SNP 2-

NO

가 , 2.5 μM NO

가 가 . cGMP analogue 8-bromo-cGMP
apoptotic body , SNP 2-
: NO , NO
NO cGMP apoptosis 가

Key words: Nitric oxide, Sodium nitroprusside, Peritoneal fluid, Embryo development.

